<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01363349</url>
  </required_header>
  <id_info>
    <org_study_id>1020-CLIN-201</org_study_id>
    <nct_id>NCT01363349</nct_id>
    <nct_alias>NCT01365299</nct_alias>
  </id_info>
  <brief_title>Phase IIb-III Study of BL-1020 Small Molecule for Schizophrenia</brief_title>
  <acronym>CLARITY</acronym>
  <official_title>A Randomized, Double-Blind, Active-Controlled,Phase 2/3 Study to Determine the Short-Term (6-Week) and Long-Term (6 Month) Cognitive and Anti-Psychotic Efficacy, Safety and Tolerability of CYP-1020 Compared to Risperidone in Patients With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioLineRx, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioLineRx, Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, active-controlled, 6 month study designed to evaluate the
      cognitive effects of treatment with CYP-1020 compared to risperidone. The primary efficacy
      endpoint will occur after 6 weeks of treatment; additional (secondary) efficacy endpoints
      will occur after 12 and 24 weeks of treatment.

      Up to 450 patients will be randomized to CYP-1020 or risperidone in a 1:1 ratio. The study
      will utilize a flexible dose escalation scheme designed to allow patients to titrate to their
      maximally tolerated dose; doses of CYP-1020 may range from a minimum of 15 mg to a maximum of
      35 mg, whereas doses of risperidone will range from a minimum of 1 mg to 3 mg BID (2-6 mg
      daily). To ensure effective blinding across all treatment groups, all patients will be
      treated twice daily with study drug and/or placebo, as indicated (i.e., double-dummy design).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    pre-planned interim analysis of the Phase II/III CLARITY trial of BL-1020 indicate that the
    trial would not meet the pre-specified primary efficacy endpoint.
  </why_stopped>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cognition</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>To evaluate the cognitive benefits of treatment with CYP-1020 (formerly known as BL-1020) compared to risperidone after 6 weeks of treatment in patients experiencing acute exacerbation of schizophrenia. Assessed by calculating difference between CYP-1020 and Risperidone on mean change from baseline to Week 6 endpoint on MATRICS Consensus Cognition Battery (MCCB) normative composite score. MCCB is a neuropsychological test battery that comprises 10 measures of 7 different cognitive areas including speed of processing, verbal learning, memory-verbal and non verbal reasoning and problem solving, visual learning, social cognition, attention/vigilance.The study was terminated after the interim analysis. MCBB total score ranges from -50 to 150. Change from Baseline by Visit (LOCF)Higher score means better cognitive functioning.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Long Term Cognition</measure>
    <time_frame>12 and 24 weeks of treatment</time_frame>
    <description>Evaluation of the cognitive benefits of treatment with BL-1020 compared to risperidone after 12 and 24 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long Term Schizophrenia Treatment</measure>
    <time_frame>Baseline and 6, 12 and 24 weeks of treatment</time_frame>
    <description>Evaluation of the antipsychotic efficacy of BL-1020 compared to risperidone after 6, 12 and 24 weeks of treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">269</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Cognitive Effect on Schizophrenic Patients</condition>
  <arm_group>
    <arm_group_label>CYP-1020</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose titration 15-35mg/day for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Risperidone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dose titration 2-6mg/day for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CYP-1020</intervention_name>
    <description>CYP-1020 (formerly known as BL-1020) is an orally available new chemical entity.</description>
    <arm_group_label>CYP-1020</arm_group_label>
    <other_name>BL-1020</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone</intervention_name>
    <arm_group_label>Risperidone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or non-pregnant or lactating female, 18-50 years of age inclusive

          2. Patients must have exhibited symptoms meeting the criteria of schizophrenia for at
             least one year, but not more than 20 years, prior to Screening

          3. Recent onset (not more than 30 days) of worsening of psychiatric symptoms at
             Screening.

          4. Currently experiencing an acute exacerbation of schizophrenia, as defined by the
             following results at Screening and Baseline:

               -  ≥70 total score on the PANSS

               -  ≥4 (moderate) on two of the following four PANSS items: (1) delusions, (2)
                  hallucinatory behaviors, (3) conceptual disorganization or (4)
                  suspiciousness/persecution, where at least one of the two items must be either
                  delusions or hallucinatory behaviors

          5. CGI-S score between 4 and 6 (moderately ill to severely ill) at the Screening and
             Baseline visits.

          6. Has exhibited a sufficient clinical response to at least one previous course of an
             anti-psychotic agent prescribed at a generally recognized therapeutic dose.

          7. Must have completed at least 5 years of formal education or its equivalent

        Exclusion Criteria:

          1. Breastfeeding or pregnant

          2. Symptoms of schizophrenia for more than 20 years at the time of screening.

          3. Psychotic symptoms that have failed to improve (based on Investigator's opinion or
             documented medical history) following sufficient treatment with therapeutic doses of
             two or more anti-psychotics agents over the preceding 2 years

          4. Prior history of neuroleptic malignant syndrome

          5. Prior history or current evidence of moderate or severe tardive dyskinesia (mild is
             acceptable).

          6. Abnormal ECG evaluation

          7. History of confirmed epilepsy or prior seizure disorder (history of a single febrile
             seizure is not exclusionary)

          8. In the opinion of the investigator, unstable medical disease (e.g., malignancy, poorly
             controlled diabetes or hypertension, ischemic cardiac disease, dilated cardiomyopathy
             or valvular heart disease, pulmonary disease, liver disease, kidney disease)

          9. Acute infectious disease (e.g., malaria, dengue fever, hepatitis A), or chronic
             infectious disease (e.g., history of AIDS or HIV positivity, tuberculosis)

         10. Likely allergy, sensitivity or intolerance to BL-1020, perphenazine, risperidone,
             paliperidone, or any of the drug product excipients

         11. Any suicide attempt within the preceding 2 years

         12. Any Substance Dependence disorder

         13. High likelihood of substance abuse

         14. Diagnosis with one of the following DSM-IV-TR Axis I diagnoses: schizophreniform
             disorder, schizoaffective disorder, bipolar disorder, substance dependency, mood
             disorder with psychotic features; psychotic disorder NOS

         15. Requiring chronic treatment with benzodiazepines

         16. Requiring chronic treatment with mood stabilizers

         17. Previously treated with clozapine within 6 months prior to screening

         18. Any abnormal clinical laboratory test result that is judged by the Investigator to be
             clinically significant

         19. History of, or serologic evidence of, acute or chronic active hepatitis B or C
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arnon Aharon, MD</last_name>
    <role>Study Chair</role>
    <affiliation>BioLineRx, Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Psychiatry, Sheath VS General Hospital, Sheath KM School of Post Graduate Medicine &amp; Research</name>
      <address>
        <city>Ahmedabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saoji Tupkari Hospital</name>
      <address>
        <city>Aurangabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spandana Nursing Home</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KHM Hospital</name>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asha Hospital</name>
      <address>
        <city>Hyderabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Psychiatry, Owaisi Hospital &amp; Research Centre</name>
      <address>
        <city>Hyderabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RK Yadav Memorial Mental Health and De-addiction Hospital</name>
      <address>
        <city>Jaipur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mahendru Psychiatric Centre</name>
      <address>
        <city>Kanpur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dreamland Nursing Home</name>
      <address>
        <city>Kolkata</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dayanand Medical College &amp; Hospital</name>
      <address>
        <city>Ludhiana</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre for Psychiatric Research, Department of Psychiatry, K.S Hegde Medical Academy</name>
      <address>
        <city>Mangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jaslok Hospital&amp;Research Centre</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JSS Medical College Hospital</name>
      <address>
        <city>Mysore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sujata Birla Hospital</name>
      <address>
        <city>Nashik</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vimhans Hospital</name>
      <address>
        <city>New Delhi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.V.Medical College</name>
      <address>
        <city>Tirupati</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deva Mental Health Care</name>
      <address>
        <city>Varanasi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vijayawada Institute of Mental Health &amp; Neurosciences</name>
      <address>
        <city>Vijayawada</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IMSP Spitalul Clinic de Psihiatrie, Sectia 14</name>
      <address>
        <city>Chisinau</city>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IMSP Spitalul Clinic de Psihiatrie, Sectia 17</name>
      <address>
        <city>Chisinau</city>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IMSP Spitalul Clinic de Psihiatrie, Sectia 8</name>
      <address>
        <city>Chisinau</city>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>pitalul Clinic Judetean de Urgenta Arad Clinica Psihiatrie</name>
      <address>
        <city>Arad</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul de Psihiatrie si Neurologie Brasov</name>
      <address>
        <city>Brasov</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Psihiatrie &quot;Prof. Dr. Al. Obregia&quot;</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Psihiatrie Dr. Alexandru Obregia Department 13</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Psihiatrie Dr. Alexandru Obregia Department 1</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Psihiatrie Dr. Alexandru Obregia Department 8</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Psihiatrie Dr. Alexandru Obregia Department 9</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul de Psihiatrie C.E.T.T.T. &quot;Sf. Stelian&quot;</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Judetean Cluj Napoca</name>
      <address>
        <city>Cluj Napoca</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Judetean de Urgenta Constanţa Clinica de Psihiatrie</name>
      <address>
        <city>Constanta</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Neuropsihiatrie Clinica de Psihiatrie nr. 2</name>
      <address>
        <city>Craiova</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul de Neuropsihiatrie Clinica de Psihiatrie I</name>
      <address>
        <city>Craiova</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Psihiatrie Socola</name>
      <address>
        <city>Iasi</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spital Clinic de Neurologie si Psihiatrie Oradea</name>
      <address>
        <city>Oradea</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Municipal &quot;Dr.Gavril Curteanu&quot; Oradea</name>
      <address>
        <city>Oradea</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul de Psihiatrie &quot;Dr. Gh. Preda&quot;</name>
      <address>
        <city>Sibiu</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Judetean de Urgenta Targoviste Clinica Psihiatrie Adulti nr. 7</name>
      <address>
        <city>Targoviste</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Judetean Mures, Clinica Psihiatrie Nr. 2</name>
      <address>
        <city>Targu-Mures</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
    <country>Moldova, Republic of</country>
    <country>Romania</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2011</study_first_submitted>
  <study_first_submitted_qc>May 31, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2011</study_first_posted>
  <results_first_submitted>April 22, 2014</results_first_submitted>
  <results_first_submitted_qc>September 17, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 18, 2014</results_first_posted>
  <last_update_submitted>September 17, 2014</last_update_submitted>
  <last_update_submitted_qc>September 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CYP-1020</title>
          <description>CYP-1020: CYP-1020 (formerly known as BL-1020) is an orally available new chemical entity.</description>
        </group>
        <group group_id="P2">
          <title>Risperidone</title>
          <description>2-6 mg, 6 months
Risperidone</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="133"/>
                <participants group_id="P2" count="136"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Randomized</title>
              <participants_list>
                <participants group_id="P1" count="133"/>
                <participants group_id="P2" count="136"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="70"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non compliance/Protocol deviations</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not reported</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>missing</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CYP-1020</title>
          <description>CYP-1020: CYP-1020 (formerly known as BL-1020) is an orally available new chemical entity.</description>
        </group>
        <group group_id="B2">
          <title>Risperidone</title>
          <description>2-6 mg, 6 months
Risperidone</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="133"/>
            <count group_id="B2" value="136"/>
            <count group_id="B3" value="269"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.3" spread="8.76"/>
                    <measurement group_id="B2" value="32.3" spread="7.97"/>
                    <measurement group_id="B3" value="32.8" spread="8.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>number of participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Romania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cognition</title>
        <description>To evaluate the cognitive benefits of treatment with CYP-1020 (formerly known as BL-1020) compared to risperidone after 6 weeks of treatment in patients experiencing acute exacerbation of schizophrenia. Assessed by calculating difference between CYP-1020 and Risperidone on mean change from baseline to Week 6 endpoint on MATRICS Consensus Cognition Battery (MCCB) normative composite score. MCCB is a neuropsychological test battery that comprises 10 measures of 7 different cognitive areas including speed of processing, verbal learning, memory-verbal and non verbal reasoning and problem solving, visual learning, social cognition, attention/vigilance.The study was terminated after the interim analysis. MCBB total score ranges from -50 to 150. Change from Baseline by Visit (LOCF)Higher score means better cognitive functioning.</description>
        <time_frame>Baseline and 6 weeks</time_frame>
        <population>Analysis for MCCB Score ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>CYP-1020</title>
            <description>CYP-1020: CYP-1020 (formerly known as BL-1020) is an orally available new chemical entity.</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>2-6 mg, 6 months
Risperidone</description>
          </group>
        </group_list>
        <measure>
          <title>Cognition</title>
          <description>To evaluate the cognitive benefits of treatment with CYP-1020 (formerly known as BL-1020) compared to risperidone after 6 weeks of treatment in patients experiencing acute exacerbation of schizophrenia. Assessed by calculating difference between CYP-1020 and Risperidone on mean change from baseline to Week 6 endpoint on MATRICS Consensus Cognition Battery (MCCB) normative composite score. MCCB is a neuropsychological test battery that comprises 10 measures of 7 different cognitive areas including speed of processing, verbal learning, memory-verbal and non verbal reasoning and problem solving, visual learning, social cognition, attention/vigilance.The study was terminated after the interim analysis. MCBB total score ranges from -50 to 150. Change from Baseline by Visit (LOCF)Higher score means better cognitive functioning.</description>
          <population>Analysis for MCCB Score ITT population.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MCCB Baseline Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" spread="13.66"/>
                    <measurement group_id="O2" value="8.2" spread="13.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCCB Week 6 Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.5" spread="12.92"/>
                    <measurement group_id="O2" value="12.5" spread="13.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Long Term Cognition</title>
        <description>Evaluation of the cognitive benefits of treatment with BL-1020 compared to risperidone after 12 and 24 weeks of treatment</description>
        <time_frame>12 and 24 weeks of treatment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Long Term Schizophrenia Treatment</title>
        <description>Evaluation of the antipsychotic efficacy of BL-1020 compared to risperidone after 6, 12 and 24 weeks of treatment</description>
        <time_frame>Baseline and 6, 12 and 24 weeks of treatment</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>CYP-1020</title>
          <description>CYP-1020: CYP-1020 (formerly known as BL-1020) is an orally available new chemical entity.</description>
        </group>
        <group group_id="E2">
          <title>Risperidone</title>
          <description>2-6 mg, 6 months
Risperidone</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>muscle rigidity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>schizophrenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="133"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>completed suicide</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>delerium</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>persecutory delusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>sleep disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>suicidal ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>pollakiuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="105" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="101" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="133"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>salivary hypersecretion</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="133"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="133"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="133"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>MUSCLE RIGIDITY</sub_title>
                <counts group_id="E1" events="32" subjects_affected="32" subjects_at_risk="133"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>TREMOR</sub_title>
                <counts group_id="E1" events="30" subjects_affected="30" subjects_at_risk="133"/>
                <counts group_id="E2" events="28" subjects_affected="28" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>AKATHISIA</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="133"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>SOMNOLENCE</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="133"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>SEDATION</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="133"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="133"/>
                <counts group_id="E2" events="26" subjects_affected="26" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>RESTLESSNESS</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="133"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="133"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Arnon Aharon</name_or_title>
      <organization>BioLineRx LTD</organization>
      <phone>972-2-548-9100 ext 135</phone>
      <email>arnona@biolinerx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

